Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).

Role of baseline HIV-1 DNA level in highly-experienced patients receiving raltegravir, etravirine and darunavir/ritonavir regimen (ANRS139 TRIO trial).

OBJECTIVE: In the ANRS 139 TRIO trial, the use of 3 new active drugs (raltegravir, etravirine, and darunavir/ritonavir), resulted in a potent and sustained inhibition of viral replication in multidrug-resistant treatment-experienced patients. The aim of this virological sub-study of the ANRS 139 TRI...

Full description

Bibliographic Details
Main Authors: Charlotte Charpentier, Catherine Fagard, Céline Colin, Christine Katlama, Jean-Michel Molina, Christine Jacomet, Benoit Visseaux, Anne-Marie Taburet, Françoise Brun-Vézinet, Geneviève Chêne, Yazdan Yazdanpanah, Diane Descamps, ANRS139 TRIO Trial study group
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3547918?pdf=render

Internet

http://europepmc.org/articles/PMC3547918?pdf=render

Similar Items